{"id":"W3087964189","doi":"10.1016/j.annonc.2020.08.1544","title":"1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Placebo; Discontinuation; Quality of life (healthcare); Nausea; Clinical trial; Clinical endpoint; Pembrolizumab; Internal medicine; Cancer; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00134937,0.0004512896,0.001147998,0.000261727,0.0002192747,0.0005460024,0.0002995481,0.0006447816,0.00759444],"category_scores_gemma":[0.001338526,0.000255064,0.001819107,0.0002715359,0.0002526618,0.0007292712,0.0005388201,0.001569675,0.0005587882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004175621,"about_ca_system_score_gemma":0.0005966605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001311798,"about_ca_topic_score_gemma":0.001746209,"domain_scores_codex":[0.9992437,0.000415905,0.00006885657,0.00008031804,0.00006457116,0.0001266447],"domain_scores_gemma":[0.9995598,0.0001474766,0.0001011518,0.00003451014,0.00003503652,0.0001219344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9188834,0.009500462,0.01714998,0.0005540127,0.002091424,0.00004447694,0.00008168711,0.0004545279,0.0074579,0.0001260361,0.001140588,0.04251542],"study_design_scores_gemma":[0.243326,0.4392569,0.2896772,0.0002632685,0.005898008,0.0002237112,0.0003161832,0.001434761,0.01228286,0.0002774573,0.00697287,0.00007074046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958026,0.001386535,0.00006831399,0.00009852208,0.00008694825,0.000146549,0.0009225687,0.00001093718,0.001477111],"genre_scores_gemma":[0.9970469,0.000442959,0.0001676829,0.00009843206,0.00004340241,0.0001664924,0.0009437188,0.000003118237,0.001087358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00759444,"threshold_uncertainty_score":0.02540594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2840961509382641,"score_gpt":0.5052354451313433,"score_spread":0.2211392941930793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}